Omicron: A SARS-CoV-2 variant of real concern

Allergy. 2022 May;77(5):1616-1620. doi: 10.1111/all.15264. Epub 2022 Feb 28.

Pia Gattinger¹, Inna Tulaeva^{1

2}, Kristina Borochova¹, Bernhard Kratzer³, Doris Trapin³, Anna Kropfmüller⁴, Winfried F Pickl^{3

5}, Rudolf Valenta^{1

2

5

6}

¹ Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
² Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.
³ Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
⁴ Österreichische Gesundheitskasse, Klinikum Peterhof, Baden, Austria.
⁵ Karl Landsteiner University of Health Sciences, Krems, Austria.
⁶ NRC Institute of Immunology FMBA of Russia, Moscow, Russia.

No abstract available

Keywords: COVID-19; Omicron; SARS-CoV-2; protective antibodies; vaccine; variants of concern.

Publication types